Large Insider Purchases
Institutional-Scale SEC Form 4 Buy Signals
The Signal of $1M+ Conviction
When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-07-06 23:28 | 2021-07-02 | AVTE | Jade Biosciences, Inc. | Sofinnova Venture Partners X, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $14.00 | 357,142 | $4,999,988 | 3,758,686 | +10.5% |
| 2021-07-06 23:38 | 2021-07-02 | CVRX | CVRx, Inc. | GLAXOSMITHKLINE PLC | 10% owner | Surgical & Medical Instruments & Apparatus | BUY | $18.00 | 275,000 | $4,950,000 | 1,007,583 | +37.5% |
| 2021-07-06 19:58 | 2021-07-01 | N-A | N/A | BLACKROCK FINANCIAL MANAGEMENT INC/DE | 10% owner, Other | Other | BUY | $9.94 | 4,979,879 | $49,500,000 | 9,989,879 | +99.4% |
| 2021-07-07 02:34 | 2021-07-01 | RAIN | N/A | BVF PARTNERS L P/IL | Director, 10% owner, Other | Other | BUY | $15.47 | 587,002 | $9,078,690 | 149,480 | +100.0% |
| 2021-07-07 01:40 | 2021-07-01 | KYMR | Kymera Therapeutics, Inc. | BVF PARTNERS L P/IL | Director, Other | Biological Products, (No Diagnostic Substances) | BUY | $47.00 | 544,166 | $25,575,802 | 208,538 | +100.0% |
| 2021-07-06 13:05 | 2021-07-02 | INTA | Intapp, Inc. | Temasek Holdings (Private) Ltd | 10% owner | Services-Prepackaged Software | BUY | $26.00 | 1,920,000 | $49,920,000 | 22,133,243 | +9.5% |
| 2021-07-02 23:11 | 2021-07-02 | YOU | Clear Secure, Inc. | Durable Capital Partners LP | 10% owner | Services-Prepackaged Software | BUY | $31.00 | 1,200,000 | $37,200,000 | 8,566,942 | +16.3% |
| 2021-07-02 17:58 | 2021-06-30 | N-A | N/A | Manufacturers Life Reinsurance Ltd | 10% owner | Other | BUY | $18.24 | 109,638 | $2,000,002 | 4,401,760 | +2.6% |
| 2021-07-02 17:34 | 2021-06-30 | N-A | N/A | Manulife (International) Ltd | 10% owner | Other | BUY | $18.24 | 328,913 | $6,000,005 | 3,096,615 | +11.9% |
| 2021-07-02 14:54 | 2021-06-10 | CRN | Coronado Global Resources Inc. | AustralianSuper Pty Ltd | 10% owner | Silver Ores | BUY | $0.65 | 28,714,759 | $18,684,694 | 188,339,807 | +18.0% |
| 2021-07-02 18:36 | 2021-06-29 | GIM | Saba Capital Income & Opportunities Fund II | Saba Capital Management, L.P. | 10% owner | Other | BUY | $5.62 | 586,946 | $3,300,221 | 25,681,684 | +2.3% |
| 2021-07-02 23:46 | 2021-06-30 | ASAN | Asana Inc. | Moskovitz Dustin A. | Director, Officer, 10% owner - President, CEO, & Chair | Services-Prepackaged Software | BUY | $63.34 | 160,000 | $10,133,664 | 3,950,000 | +4.2% |
| 2021-07-03 04:54 | 2017-12-07 | KLR | N/A | Miotto Neil | Director, 10% owner | Other | BUY | $10.00 | 362,368 | $3,623,680 | 3,218,975 | +12.7% |
| 2021-07-03 03:15 | 2021-07-01 | FTCV | N/A | Luxor Capital Group, LP | 10% owner | Other | BUY | $12.57 | 334,700 | $4,207,547 | 52,208 | +100.0% |
| 2021-07-03 00:04 | 2021-07-01 | CVRX | CVRx, Inc. | Jain Mudit K. | Director | Surgical & Medical Instruments & Apparatus | BUY | $18.03 | 223,222 | $4,025,094 | 933,383 | +31.4% |
| 2021-07-03 00:03 | 2021-07-02 | CVRX | CVRx, Inc. | Pardo Geoffrey B | Director | Surgical & Medical Instruments & Apparatus | BUY | $18.00 | 275,000 | $4,950,000 | 1,829,022 | +17.7% |
| 2021-07-02 23:48 | 2021-06-30 | PLSE | PULSE BIOSCIENCES, INC. | DUGGAN ROBERT W | Director, 10% owner | Surgical & Medical Instruments & Apparatus | BUY | $16.40 | 3,048,780 | $49,999,992 | 14,708,561 | +26.1% |
| 2021-07-03 00:07 | 2021-06-30 | LRMR | Larimar Therapeutics, Inc. | Flynn James E | Director, 10% owner, Other | Pharmaceutical Preparations | BUY | $8.75 | 685,710 | $5,999,963 | 1,943,420 | +54.5% |
| 2021-07-02 02:45 | 2021-06-29 | ELEV | N/A | Qiming U.S. Healthcare Fund II, L.P. | 10% owner | Other | BUY | $16.00 | 312,500 | $5,000,000 | 2,370,142 | +15.2% |
| 2021-07-02 02:01 | 2021-06-29 | GRPH | LENZ Therapeutics, Inc. | Jerel Davis | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $17.00 | 180,000 | $3,060,000 | 1,707,719 | +11.8% |
| 2021-07-02 00:03 | 2021-06-30 | N-A | N/A | Manulife (International) Ltd | 10% owner | Other | BUY | $21.14 | 378,353 | $8,000,001 | 26,690,979 | +1.4% |
| 2021-07-01 23:43 | 2021-06-30 | N-A | N/A | Manufacturers Life Insurance Co (Bermuda Branch) | 10% owner | Other | BUY | $21.14 | 236,470 | $5,000,000 | 10,218,756 | +2.4% |
| 2021-07-02 00:04 | 2021-06-30 | N-A | N/A | Manulife Life Insurance Co | 10% owner | Other | BUY | $18.24 | 109,638 | $2,000,002 | 1,115,645 | +10.9% |
| 2021-07-01 23:44 | 2021-06-30 | N-A | N/A | Manufacturers Life Insurance Co (Bermuda Branch) | 10% owner | Other | BUY | $18.24 | 219,276 | $4,000,003 | 1,497,605 | +17.2% |
| 2021-07-02 02:01 | 2021-06-29 | GRPH | LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $17.00 | 180,000 | $3,060,000 | 1,707,719 | +11.8% |
| 2021-07-01 23:24 | 2021-06-29 | ELEV | N/A | Cormorant Asset Management, LP | Other | Other | BUY | $16.00 | 250,000 | $4,000,000 | 2,233,168 | +12.6% |
| 2021-07-02 00:08 | 2020-05-13 | ZEV | N/A | Miotto Neil | Director | Other | BUY | $10.00 | 650,000 | $6,500,000 | 6,385,000 | +11.3% |
| 2021-07-02 00:27 | 2021-06-29 | ELEV | N/A | venBio Global Strategic Fund III, L.P. | 10% owner | Other | BUY | $16.00 | 625,000 | $10,000,000 | 2,608,167 | +31.5% |
| 2021-07-02 00:39 | 2021-06-29 | GRPH | LENZ Therapeutics, Inc. | Samsara BioCapital, L.P. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $17.00 | 500,000 | $8,500,000 | 37,753 | +100.0% |
| 2021-07-02 01:29 | 2021-06-29 | ELEV | N/A | Aisling Capital IV, LP | 10% owner | Other | BUY | $16.00 | 187,500 | $3,000,000 | 2,834,910 | +7.1% |
| 2021-07-01 01:09 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Yang Rick | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 1,050,000 | $19,950,000 | 7,692,298 | +15.8% |
| 2021-07-01 00:59 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | New Enterprise Associates 17, L.P. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 1,050,000 | $19,950,000 | 7,692,298 | +15.8% |
| 2021-07-01 01:02 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Chang Carmen | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 1,050,000 | $19,950,000 | 7,692,298 | +15.8% |
| 2021-07-01 00:00 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Versant Venture Capital VI, L.P. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 157,895 | $3,000,005 | 2,097,938 | +8.1% |
| 2021-07-01 04:29 | 2021-06-28 | BHG | NeueHealth, Inc. | Chang Carmen | 10% owner | Hospital & Medical Service Plans | BUY | $18.00 | 1,944,444 | $34,999,992 | 23,983,073 | +8.8% |
| 2021-07-01 04:31 | 2021-06-28 | BHG | NeueHealth, Inc. | Makhzoumi Mohamad | Director, 10% owner | Hospital & Medical Service Plans | BUY | $18.00 | 1,944,444 | $34,999,992 | 23,983,073 | +8.8% |
| 2021-07-01 01:05 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Makhzoumi Mohamad | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 1,050,000 | $19,950,000 | 7,692,298 | +15.8% |
| 2021-07-01 01:04 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Landsman Liza | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 1,050,000 | $19,950,000 | 7,692,298 | +15.8% |
| 2021-06-30 16:52 | 2021-06-28 | DCTH | DELCATH SYSTEMS, INC. | Rosalind Advisors, Inc. | Director | Surgical & Medical Instruments & Apparatus | BUY | $11.56 | 500,000 | $5,780,000 | 416,000 | +100.0% |
| 2021-07-01 04:28 | 2021-06-28 | BHG | NeueHealth, Inc. | Behbahani Ali | 10% owner | Hospital & Medical Service Plans | BUY | $18.00 | 1,944,444 | $34,999,992 | 23,983,073 | +8.8% |
| 2021-07-01 01:01 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Behbahani Ali | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 1,050,000 | $19,950,000 | 7,692,298 | +15.8% |
| 2021-06-30 23:08 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Cormorant Asset Management, LP | Other | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 600,000 | $11,400,000 | 3,202,200 | +23.1% |
| 2021-07-01 04:30 | 2021-06-28 | BHG | NeueHealth, Inc. | Florence Anthony A. Jr. | 10% owner | Hospital & Medical Service Plans | BUY | $18.00 | 1,944,444 | $34,999,992 | 23,983,073 | +8.8% |
| 2021-07-01 01:02 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Florence Anthony A. Jr. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 1,050,000 | $19,950,000 | 7,692,298 | +15.8% |
| 2021-07-01 04:33 | 2021-06-28 | BHG | NeueHealth, Inc. | Sonsini Peter W. | 10% owner | Hospital & Medical Service Plans | BUY | $18.00 | 1,944,444 | $34,999,992 | 23,983,073 | +8.8% |
| 2021-07-01 01:08 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Sonsini Peter W. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 1,050,000 | $19,950,000 | 7,692,298 | +15.8% |
| 2021-07-01 04:33 | 2021-06-28 | BHG | NeueHealth, Inc. | Walker Paul Edward | 10% owner | Hospital & Medical Service Plans | BUY | $18.00 | 1,944,444 | $34,999,992 | 23,983,073 | +8.8% |
| 2021-07-01 01:08 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Walker Paul Edward | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 1,050,000 | $19,950,000 | 7,692,298 | +15.8% |
| 2021-07-01 02:56 | 2021-06-28 | ASAN | Asana Inc. | Moskovitz Dustin A. | Director, Officer, 10% owner - President, CEO, & Chair | Services-Prepackaged Software | BUY | $63.46 | 320,000 | $20,306,304 | 3,790,000 | +9.2% |
| 2021-07-01 00:05 | 2021-06-28 | GLUE | Monte Rosa Therapeutics, Inc. | Bolzon Bradley J PhD | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $19.00 | 157,895 | $3,000,005 | 2,097,938 | +8.1% |
Institutional Conviction in Form 4
Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.
Filtering the Market Noise
Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.